Vor BioPharma Inc (VOR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$25.05+3.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -13.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VOR — director transition
Dated 2026-07-07
Director — Andrew Levin, M.D., Ph.D.: Dr. Andrew Levin resigned as a Director of Vor Biopharma Inc.
Why it matters: U.S. regulatory approval is crucial for Vor Bio's growth. It can validate the therapy's potential.
Supportive ifThere will be a U.S. regulatory submission for telitacicept based on good Phase 3 data.
Worry ifTelitacicept has not submitted to U.S. regulators, even with good Phase 3 data.
Why it matters: When a director leaves, it can change the company’s strategy. This may lower investor confidence.
Worry ifManagement has a clear plan to deal with the director's departure.
Less concerning ifNo clear plan or negative commentary on the impact of the departure.
Why it matters: Keeping capital is vital for operations and growth. New funding can help support this.
Supportive ifA new funding round or partnership was announced to boost capital resources.
Worry ifNot getting more funding raises worries about cash flow.
Why it matters: A recent director left. This may change company strategy and stability. It can affect investor trust.
Worry ifA new director with strong industry experience has been appointed.
Less concerning ifThere are no new leaders or more departures.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$275 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $948 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,592 loss on $10,000 · 85.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company needs to secure funding through private placements to support operations. New funding would show financial health.
Supportive ifAnnouncement of a new private placement raising at least $50 million.
Worry ifThere are no new funding announcements or failed private placements.
Why it matters: Stable leadership is important for the company's future. Changes may show problems inside.
Worry ifA new board member was announced or current leaders were stabilized.
Less concerning ifMore director resignations or big changes in the board happened.
Why it matters: Changes in leadership can impact company plans and investor trust. Stability helps growth.
Watch forNew board members can take positive actions. This can improve the company's direction.
Also watch forInvestors may react negatively. They could also face more leadership issues after the change.